Form 8-K Aurinia Pharmaceuticals For: Nov 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Aurinia Pharmaceuticals (AUPH) PT Raised to $9 at RBC Capital
November 11, 2024 6:20 AM ESTRBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $9.00 (from $8.00) while maintaining a Outperform rating.
The analyst comments "Aurinia's Q3/24 product revenues of $55.5MM (+36% y/y) were ~2% ahead of estimates. Management reiterated its 2024 LUPKYNIS net revenue... More
